Beam Therapeutics Inc. BEAM
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using base editing technology. The company designs therapies that aim to make targeted, single-base changes in DNA or RNA, with the goal of precisely correcting disease-causing mutations at the molecular level. Beam Ther…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees522
TickerBEAM
Statistics
Market Cap$3.38B
Revenue (TTM)$139.7M
Net Income-$80.0M
Net Margin-57.2%
EPS$-0.81
P/E-36.30
P/S18.45
P/B2.51
EV/EBITDA-5.65
ROE-5.8%
Dividend Yield—
Price$32.91
Data: Twelve Data · Revenue = mcap / P/S